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A Proposed Mechanism for the Induction
of Cytotoxic T Lymphocyte Production
by Heat Shock Fusion Proteins
among the few exceptions to this rule. When injected
into mice in saline solution (PBS) without added adju-
vants, several of these fusion proteins were previously
shown to stimulate the production of CD8 CTL that rec-
ognize short peptide epitopes (8±10 amino acids in
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mechanisms that permit these hsp to be effective withCanada
such diverse fusion partners and that enable the hsp
fusion proteins to serve as effective immunogens for
CD8 T cells without requiring adjuvants, we studied theSummary
immunogenic activities of fusion proteins prepared from
the 65 kDa hsp from Mycobacterium bovis, BCG strainA 65 kDa mycobacterial heat shock protein (hsp65),
(here called hsp65).fused to a polypeptide that contains an octapeptide
The principal fusion partner used in this study is a(SIYRYYGL) agonist for a particular T cell receptor
polypeptide that contains an octapeptide sequence,(2C TCR), stimulated C57BL/6 mice as well as CD4-
SIYRYYGL (hereafter called SYRGL; Udaka et al., 1996),deficient mice to produce CD81 cytolytic T lympho-
which together with Kb serves as a potent stimulator ofcytes (CTL) to the fusion partner's octapeptide. This
CD8 T cells having the TCR of a CTL clone called 2Cand other hsp65 fusion proteins but not native hsp65
(Kranz et al., 1984). This peptide was identified in aitself stimulated dendritic cells in vitro and in vivo to
synthetic peptide library and, so far as is known, doesupregulate the levels of MHC (class I and II) and co-
not occur in nature. We have relied here on the use ofstimulatory (B7.2) molecules. The results suggest a
various T cells that express 2C TCR, particularly naivemechanism for the general finding that hsp fusion pro-
2C T cells (Cho et al., 1999), as specific probes to obtainteins, having fusion partners of widely differing lengths
evidence that (1) dendritic cells are more effective thanand sequences, elicit CD8 CTL to peptides from the
macrophages in presenting the processed hsp fusionfusion partners without requiring exogenous adju-
protein to naive CD8 T cells, (2) dendritic cells are stimu-
vants or the participation of CD41 T cells.
lated directly by each of several hsp65 fusion proteins
tested but not by ªnativeº hsp65 itself to increase sur-
Introduction face expression of MHC class I and II and costimulatory
(B7.2) molecules, and (3) CD4 T cells are not required
When injected with diverse adjuvants, protein antigens for the fusion protein's ability to elicit production of CD8
usually stimulate the production of high-affinity IgG anti- CTL in vivo. Taken together, the results begin to suggest
bodies, indicating that they activate CD4 T helper cells an explanation for the general finding that diverse solu-
as well as B cells. These procedures generally fail, how- ble heat shock fusion proteins, regardless of the length
ever, to elicit effective CD8 T cell responses. The reason, or sequence of the fusion partners, stimulate CD8 T cell
according to current views, is that the short peptides responses to peptides derived from the fusion partners
that are needed, in association with MHC class I mole- without requiring exogenous adjuvants. The findings are
cules, to stimulate CD8 T cells arise from proteolytic of particular interest in view of the need to develop
cleavage of cytosolic proteins. Since injected protein protective vaccines against intracellular pathogens for
antigens are generally unable to cross cellular lipid which current immunization strategies are inadequate
membranes, they fail to gain entry to the proper cytosolic (e.g., against HIV-1, human papilloma virus, various her-
ªMHC class I processing pathwayº and are thus unable pes viruses, and malaria).
to stimulate the production of CD8 T cells. Although
there is evidence of alternative cellular pathways for Results
processing some exogenous proteins to form peptide
MHC class I complexes (Gromme et al., 1999; Sigal et Design and Characterization of Heat Shock Fusion
al., 1999), it remains generally true that protein antigens Protein hsp65-P1
normally fail to stimulate significant CD8 cytolytic T lym- As shown in Figures 1A and 1B, the principal fusion
phocytes (CTL) responses (Rock, 1996). protein used in this report contains the polypeptide P1
Mycobacterial heat shock proteins (hsp) fused with fused to the C terminus of hsp65. P1 includes the octa-
large protein fragments termed fusion partners may be peptide SYRGL, which behaves in association with Kb
as a strong agonist for the TCR on 2C T cells (Sykulev
et al., 1998). The sequences that flank the octapeptide§ To whom correspondence should be addressed (e-mail: hneisen@
in P1 were chosen because they correspond to thosemit.edu).
k These authors contributed equally to this work. known to be effectively cleaved intracellularly in two un-
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related proteins: ovalbumin (Falk et al., 1992) and a-keto-
glutaraldehyde dehydrogenase (Udaka et al., 1992; Fig-
ure 1A, see arrows). To determine if the P1 polypeptide,
alone or linked as a fusion partner to hsp65, could be
cleaved intracellularly to liberate the SYRGL octapep-
tide, we transfected plasmids containing sequences for
P1 or hsp65-P1 into EL4 cells (H-2b). Because relatively
few of the transiently transfected cells were expected to
express P1 or hsp65-P1, the transfected cell population
was not used in cytolytic assays as targets for 2C CTL.
Instead, we examined their ability to stimulate naive 2C
T cells. As shown in Figure 1C, 80%±90% of these naive
T cells were stimulated to express the acute activation
marker CD69 in response to EL4 cells transfected with
either the P1 or hsp65-P1 plasmids, while virtually none
of the naive T cells were activated by cells transfected
with the empty plasmids (Figure 1C, ªVector,º shaded
histograms). These results indicate that in these trans-
fected cells, P1 and hsp65-P1 can be cleaved to release
the octapeptide, which is then presented by Kb.
C57BL/6 Mice Produce SYRGL-Specific CD81
Cytolytic T Cells in Response to hsp65-P1
Before immunizing mice with hsp65-P1, we first had to
be sure that CD8 T cells that can recognize the SYRGL
octapeptide are present in normal C57BL/6 (H-2b) mice.
The mice were therefore injected with SYRGL peptide
in adjuvant (TiterMaxGold), and their spleen cells were
maintained in culture for several weeks (see Experimen-
tal Procedures) and subsequently tested in a standard
cytotoxicity assay. As shown in Figure 1D, the cell line's
lysis of Kb1 target cells (T2-Kb) was SYRGL dependent,
indicating the presence in these mice of T cells that can
respond to SYRGL±Kb complexes.
To determine if the hsp65-P1 fusion protein could
stimulate (ªprimeº) anti-SYRGL CTL in vivo, normal
C57BL/6 mice were injected subcutaneously with theFigure 1. Design and Characterization of Heat Shock Fusion Protein
fusion protein in saline without added adjuvants. Eachhsp65-P1
mouse received two injections, 1 week apart. Seven(A) P1 peptide. When liberated from P1, SIYRYYGL (boldface) binds
days after the second injection, cells from regionalto Kb to form the peptide±MHC complex recognized by the 2C TCR.
In P1, SIYRYYGL is flanked 59 and 39 by sequences that lie immedi- lymph nodes and spleen were restimulated in culture
ately upstream and downstream, respectively, of peptide bonds with SYRGL (1 mM) in the absence of exogenous cyto-
that are cleaved (see arrows) in murine cells to liberate naturally kines and tested after 6 days for CTL activity in a 4 hr
occurring peptides (SIINFEKL from ovalbumin [Ova] and LSPFPFDL
cytolytic assay, using 51Cr-labeled Kb1 target cells (T2-from a-ketoglutaraldehyde dehydrogenase [aKG]) (Falk et al., 1992;
Kb; see Experimental Procedures). Of 40 injected mice,Udaka et al., 1992).
35 produced CTL whose lysis of the Kb1 target cells was(B) Diagram of the hsp65-P1 fusion protein, showing P1 at the C
terminus of hsp65. SYRGL dependent (see Figure 2A for a representative
(C) Evidence that P1 and hsp65-P1 are processed intracellularly to response). C57BL/6 mice treated in exactly the same
yield the SYRGL octapeptide. Forty-eight hours after transfection way with equimolar amounts of various controls (hsp65,
with mammalian expression vectors (VR1055 and pCINeo), con-
P1, a mixture of hsp65 and P1, or SYRGL alone) all failedtaining sequences that encode P1 and hsp65-P1, respectively, EL4
to yield SYRGL-specific CTL (Figure 2A). As little as 1cells were incubated for 18 hr with an equal number of naive 2C T
mg (0.015 nmol) of hsp65-P1 could elicit an anti-SYRGLcells. Histograms show the percentage of live, 2C1CD81 cells that
were stimulated to upregulate the activation marker CD69. The re- CTL response. A control fusion protein made by fusing
sponses of these naive T cells to control EL4 cells, transfected with the P1 sequence to the C terminus of another bacterial
the empty (Vector) plasmids, are shown as shaded histograms. protein, chosen simply for ease of purification (the E.
(D) Normal C57BL/6 mice have T cells that can recognize the
coli maltose binding protein [Mal-P1]), was z10±100SYRGL±Kb complex. A CD81 T cell line, derived from C57Bl/6 mice
times less effective in these assays (Figure 2B) and with-immunized with the SYRGL peptide in adjuvant, specifically lysed
out any detectable effect in others (Figures 3±6). Re-T2-Kb target cells in a SYRGL-dependent manner. A highly cytolytic
long-term cultured 2C CTL clone (L3.100) is shown for comparison. moval of CD8 T cells by magnetic sorting showed that
the cytolytic response to hsp65-P1 was due to CD8 T
cells (Figure 2C). These results demonstrate that hsp65-
P1, without added adjuvants, can elicit a CD8 T cell
response to the fusion partner.
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Figure 3. Macrophages and Dendritic Cells Incubated Briefly with
hsp65-P1 Become Target Cells for a SYRGL-Specific CTL Clone
51Cr-labeled splenic dendritic cells (ªspl dcº), bone marrow±derived
dendritic cells (ªbm dcº), or purified macrophages (ªm`º) isolated
from peritoneal lavage, all from B6 (H-2b) mice, were incubated
for 4 hr with a 2C CTL clone (L3.100; see Figure 1D) and various
concentrations of hsp65-P1 or Mal-P1. CTL:target cell ratio (E:T) of
5:1. Unfilled symbols show lysis when the control fusion protein
(Mal-P1) was used in place of hsp65-P1.
were tested for their ability to present processed
hsp65-P1 and serve as target cells in cytolytic assays,
using a well-established SYRGL-Kb-specific CTL clone
(L3.100) as an effector. When dendritic cells and macro-
phages were 51Cr labeled and incubated with hsp65-P1
for 4 hr, they were lysed effectively and to about the
same extent (Figure 3). No significant lysis was ob-
served, however, when the control fusion protein Mal-
P1 was used in place of hsp65-P1, suggesting that
processing of hsp65-P1 by these APC was not due to
indiscriminate extracellular proteolysis.
Cytolytic reactions with potent CTL clones such as
L3.100 can be exquisitely sensitive, detecting very few
and perhaps as few as one cognate peptide±MHC com-
plex per target cell (Sykulev et al., 1996). Therefore, we
used a more discriminating assay in which dendritic
cells and macrophages that had been incubated with
Figure 2. Response of C57BL/6 Mice to hsp65-P1 hsp65-P1 were compared for their ability to stimulate
(A) CD8 CTL that recognize the SYRGL±Kb complex are produced naive 2C T cells. As shown in Figure 4, when the dendritic
in C57BL/6 mice injected with hsp65-P1 in PBS but not in those
cells were incubated with hsp65-P1 overnight and theninjected similarly with equimolar amounts of various controls (a mix-
with naive 2C T cells, the naive T cells were stimulatedture of P1 and hsp65, the SYRGL octapeptide, the P1 polypeptide
to (1) express CD69, (2) proliferate, and (3) secrete IL-2itself, hsp65 itself).
(B) SYRGL-specific CTL in mice injected as in (A) with various and IFNg. In contrast, the macrophage preparations
amounts of hsp65-P1, 0.015±1.5 nmol (1±100 mg), or a control fusion stimulated none of these responses. (It may be that
protein in which P1 is linked to the C terminus of a maltose-binding activated macrophages would have behaved differently,
protein (Mal-P1, 1.5 nmol, 80 mg).
but we deliberately focused on nonactivated macro-(C) Depletion of CD81 T cells eliminates the SYRGL-specific CTL
phages and dendritic cells to simulate conditions in theproduced by mice injected with hsp65-P1. Lymph node and spleen
unimmunized animal.) The responses elicited by den-cells from C57BL/6 mice immunized with 1.5 nmol of hsp65-P1 or
Mal-P1 were cultured for 6 days and then depleted of CD8 T cells by dritic cells could be inhibited by the clonotypic, anti-2C
magnetic sorting. The untreated, CD8-depleted, and CD8-enriched TCR antibody (1B2; Figure 4C), indicating that they were
populations (30%, 1%, and 90% CD81 T cells, respectively) were mediated by ligation of the 2C TCR. The requirement
analyzed in a 4 hr cytolytic assay.
for the hsp65 moiety in the hsp65-P1 fusion protein isIn (A), (B), and (C) target cells are T2-Kb plus 1 mM SYRGL. In (B)
emphasized by the result that the naive 2C T cells wereand (C) lysis of T2-Kb target cells in the absence of added SYRGL
stimulated to express CD69 by dendritic cells that hadpeptide is indicated by unfilled symbols.
been incubated with hsp65-P1 but not by those that
had been incubated with the control fusion protein Mal-
P1 (Figure 4A).Dendritic Cells and Macrophages Differ in Ability to
Incubation of dendritic cells with various controls (P1Serve as Antigen-Presenting Cells for hsp65-P1
alone, hsp65 alone, or a mixture of hsp65 plus P1) inTo identify antigen-presenting cells (APC) that mediate
place of hsp65-P1 did not stimulate 2C T cells to secretein vivo CD8 T cell responses, purified preparations of
IFNg. However, of all the controls, the P1 peptide wasAPC from C57BL/6 mice (dendritic cells from spleen or
bone marrow and macrophages from peritoneal lavage) exceptional in that it exhibited some activity: with both
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then evaluated their ability to stimulate naive 2C T cells.
As shown in Figure 5A, the naive cells proliferated and
produced substantial amounts of IL-2 in response to
dendritic cells that had been incubated with concentra-
tions of hsp65-P1 in the 0.1±.01 mM range. In contrast,
the responses by naive cells were negligible when mac-
rophages were used in place of dendritic cells or when
the Mal-P1 control fusion protein was used at concentra-
tions of up to 1 mM (Figure 5A). Together, these data
suggest that dendritic cells are more effective than mac-
rophages in processing and presenting the octapeptide
from hsp65-P1.
Heat Shock Fusion Proteins Stimulate Dendritic
Cells Directly
The distinctive ability of hsp65-P1 to stimulate naive 2C
(anti-SYRGL) T cells in vitro only in the presence of
dendritic cells led us to examine the effect of hsp65-P1
on dendritic cells directly. As shown in Figure 6A, when
immature bone marrow±derived dendritic cells (day 6 in
culture) were incubated overnight with various concen-
trations of hsp65-P1, the dendritic cell surface level of
Figure 4. Dendritic Cells but Not Macrophages Generate Sustained an MHC class I molecule (Kb) was increased. The extent
Responses from Naive 2C T Cells to hsp65-P1 of the increase depended on the hsp65-P1 concentra-
Splenic dendritic cells and peritoneal lavage macrophages were tion, and no increase was seen when hsp65-P1 was
purified by magnetic sorting and incubated for 18±24 hr with equimo- replaced by a series of control proteins and peptides
lar concentrations of hsp65-P1 or Mal-P1 (in [A]) and hsp65-P1 or
(hsp65 alone, P1 alone, SYRGL, Mal-P1, or a monoclonalunmodified hsp65 (in [B]) before adding naive 2C T cells.
IgG antibody [anti-2,4,6, trinitrophenyl]).(A) Expression of the activation marker CD69. Hsp65-P1 or Mal-P1
Other hsp65 fusion proteins, having various fusionwere added to purified splenic dendritic cells, macrophages, or
media alone (no APC) at 15 nM (z1 mg/ml). After 24 hr, purified partners (influenza virus nucleoprotein or the E7 subunit
naive 2C T cells were added (T cell:APC ratio of 1:1), and 18 hr later of human papilloma virus), also elicited increased ex-
cells were analyzed for CD69, gating on propidium iodide±negative pression of Kb on the dendritic cells (Figure 6A). It is
2C1CD81 cells. The percentage of 2C T cells with increased expres-
important to note, however, that unmodified hsp65sion of CD691 is indicated.
(ªhsp65 onlyº in Figures 6A and 6B) consistently failed(B) Dendritic cells or macrophages were incubated with hsp65-P1
to stimulate dendritic cell upregulation of Kb.or hsp65 before adding the naive 2C T cells as in (A), and incubation
was continued for an additional 18 hr (IL-2 assay), 60 hr (proliferation All of the fusion proteins as well as unmodified hsp65
assay), or 48 hr (IFNg assay). ªNo Agº means the dendritic cells and were produced as recombinant proteins in E. coli and
2C T cells were present but hsp65-P1 and hsp65 were absent; ªNo contained trace levels of endotoxin (lipopolysaccharide
T cellsº means hsp65-P1 and APC were present but the 2C T cells
[LPS]). An endotoxin standard by itself evoked a weakwere omitted.
response at the highest concentration tested (5 endo-(C) Inhibition of responses by a clonotypic monoclonal antibody to
toxin units [EU]/ml, Figure 6B). Because of molecularthe 2C TCR (IB2). Bone marrow±derived dendritic cells were incu-
bated with 10 mg/ml hsp65-P1 overnight. Equal numbers of naive weight heterogeneity of LPS, conversion of endotoxin
2C T cells were then added in the presence or absence of 1B2 Fab units into LPS weight and mole units is highly approxi-
fragments (25 mg/ml). After an additional 18 hr, cells and superna- mate. But, if one EU corresponds to about 5 ng LPS
tants were analyzed, respectively, for CD69 expression (left panel)
and the ªaverageº molecular weight of LPS is taken toand IL-2 production ([3H]thymidine incorporation by IL-2-responsive
be z10,000, LPS would appear to be somewhat moreHT2 cells, right panel).
effective than hsp65 fusion proteins in activating den-
dritic cells. Nevertheless, the effects of the fusion pro-
teins seemed clearly not to be due to endotoxin contami-dendritic cells and macrophages it stimulated CD69 ex-
pression, and with dendritic cells but not with macro- nants, because when hsp65-P1, hsp65, or Mal-P1 were
each added in amounts that resulted in addition of equiv-phages it induced proliferation and IL-2 secretion by the
naive 2C T cells (data not shown). It is likely that the P1 alent EU units to the dendritic cells, increased expres-
sion of Kb was elicited only by hsp65-P1 (Figure 6B).peptide itself is subject to proteolysis by these APC,
particularly by dendritic cells, but whether extracellularly Moreover, when the data from Figure 6A were plotted
against the EU concentrations attributable to the con-or in some intracellular compartment is not clear. What-
ever the explanation, it should be noted that the P1 trols and fusion proteins, it was evident that each of the
four hsp65 fusion protein preparations but none of thepolypeptide did not stimulate CD8 CTL production in
vivo under conditions in which the hsp65-P1 fusion pro- controls stimulated increased expression of MHC class
I protein. Finally, all the hsp65 fusion proteins elicitedtein was consistently effective (Figure 2A). In addition,
as is shown later, P1 failed to activate dendritic cells increases in MHC class I expression on dendritic cells
from C3H/HeJ mice, a strain known to be unresponsive(see Figure 6 below).
To examine the difference between dendritic cells and to LPS (due to a mutation in the Toll4 receptor) (Poltorak
et al., 1998). Taken together, the findings demonstratemacrophages more closely, we incubated these cells
with various concentrations of the fusion proteins and that hsp65 fusion proteins can activate dendritic cells.
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Besides stimulating the dendritic cells (bone marrow
derived and maintained in culture with GM-CSF for 6
days) to express increased levels of MHC class I, the
hsp fusion proteins stimulated increased expression of
MHC class II and B7.2 (CD86) (Table 1); the level of CD40
was, however, only marginally affected. Native hsp65
did not affect expression of MHC class II or B7.2, just
as it failed to affect levels of MHC class I.
Activated Dendritic Cells In Vivo
That the dendritic cell changes could also be elicited in
vivo was indicated by the finding that 24 hr after injecting
hsp65-P1 (in saline) subcutaneously into mice, myeloid
dendritic cells (but not lymphoid dendritic cells) from
lymph nodes draining the site of injection showed in-
creased expression of Kb (Figure 5B).
To determine if activated dendritic cells were espe-
cially effective in vivo, normal B6 mice were adoptively
transferred with 2 3 106 naive 2C cells (from 2C TCR
transgenic mice; Cho et al., 1999), and the next day the
recipients were injected in a hind footpad with 8 3 105
dendritic cells. The dendritic cells had been incubated
overnight with or without hsp65-NP (to generate acti-
vated or nonactivated dendritic cells, respectively) and
then incubated for 2 hr with SYRGL peptide at various
concentrations (0, 1026, 1027, 1028, and 1029 M) and
washed just before the cells were injected. Twenty-four
hours later, 2C CD81 T cells from the draining popliteal
lymph nodes were examined for CD69 expression as
evidence of having been antigenically stimulated. As
shown in Figure 5C, when the peptide concentration
was 10±9 M, the activated dendritic cells were consider-
ably more effective than the nonactivated dendritic cells
in stimulating the naive 2C T cells to express CD69.
When pulsed with the peptide at 10±1000 times higher
concentrations, activated and nonactivated dendritic
cells were about equally effective, stimulating CD69 re-
sponses of the 2C CD81 cells at about the level seen in
Figure 5C, bottom panel.
Stimulation of CD8 CTL Production In Vivo
by the hsp65-P1 Fusion Protein Does Not
Require the Participation of CD4 T Cells
The ability of the hsp fusion proteins to directly stimulate
dendritic cells suggested that CD4 T cells might not be
necessary for the CD8 T cell response elicited in vivo
Figure 5. Comparison of Dendritic Cells' and Macrophages' Ability by the fusion proteins. To test this possibility, we immu-
to Stimulate T Cell Responses at Limiting Antigen Dose In Vitro, and nized CD4 knockout mice (CD42/2) using the same regi-
Behavior of hsp65 Fusion Protein±Activated Dendritic Cells in Vivo
men as before (Figure 2) and assessed their ability to
(A) Fresh splenic dendritic cells or macrophages were incubated produce SYRGL-specific CTL. As seen in a representa-with various concentrations of hsp65-P1 or Mal-P1 fusion proteins
tive response in Figure 6C, the CD42/2 mice producedfor about 18 hr before adding purified naive 2C T cells (see Figure
CTL in response to hsp65-P1 but not in response to the4). Supernatants were sampled 18 hr later to determine IL-2 levels
(upper panel). [3H]thymidine was added at 48 hr, and cells were
harvested after an additional 18 hr to assess T cell proliferation
(lower panel).
(B) Activation of dendritic cells in vivo. Myeloid dendritic cells from deficient mice). Twenty-four hours after the footpad injection, 2C
lymph nodes draining a subcutaneous site where hsp65-P1 was CD81 T cells in the draining popliteal lymph node were examined
injected 24 hr previously show increased expression of MHC-I (Kb) for CD69 expression. Frequency of CD691 2C CD81 T cells in a
(lower panel) compared to myeloid dendritic cells from lymph nodes lymph node draining the site where activated (control) dendritic
draining an uninjected site (no treatment, upper panel) cells (not pulsed with peptide) were injected (upper panel) or where
(C) Dendritic cells activated with a noncognate hsp fusion protein SYRGL peptide-pulsed (1 3 10±9 M) unactivated dendritic cells or
(hsp65-NP) and pulsed with 10±9 M SYRGL peptide are more effec- activated dendritic cells were injected (middle panel and lower
tive than nonactivated, similarly pulsed dendritic cells in stimulating panel, respectively). Percentages of CD691 2C cells are shown.
naive T cells in vivo. Dendritic cells (8 3 105) were injected into a Geometric mean fluorescence values for MHC-I (Kb) on dendritic
hind footpad of normal B6 mice that had been injected intravenously cells that had been incubated prior to footpad injection with or
with 2 3 106 naive 2C TCR1 cells (from 2C TCR transgenic RAG- without hsp65-NP were 379 and 97, respectively (data not shown).
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Figure 6. Hsp65 Fusion Proteins Can Directly Stimulate Dendritic Cells and hsp65-P1 Elicits CD4 T Cell±Independent Production of CTL
Purified bone marrow±derived dendritic cells were incubated for 24 hr with various concentrations of hsp65-P1 or other hsp65 fusion proteins,
having as fusion partners influenza virus nucleoprotein (hsp65-NP) or human papilloma virus, type 16, E7 subunit (hsp65-E7 preparations 1
and 2) or with controls (hsp65 alone, P1 alone, E7 alone, an anti-TNP IgG antibody). MHC class I protein levels on the dendritic cells were
then determined by flow cytometry by gating on propidium iodide±negative CD11c1 cells and using the Y3 antibody which recognizes both
H-2b (Kb) and H-2k MHC class I. MHC class I levels are shown as geometric mean fluorescence; the levels on untreated dendritic cells are
represented by a dashed horizontal line.
(A) Dendritic cell MHC class I expression plotted as a function of protein concentration of the added hsp fusion proteins and control proteins.
Upper panel shows dendritic cells from C57BL/6 mice. Lower panel shows dendritic cells from C3H/HeJ mice.
(B) The dendritic cell MHC class I expression values from (A) are plotted as a function of endotoxin concentration (calculated from the
endotoxin levels present in the added hsp fusion proteins and other proteins). Upper panel shows dendritic cells from C57BL/6 mice. Lower
panel shows dendritic cells from C3H/HeJ mice.
(C) Hsp65-P1 stimulates production of CTL (anti-SYRGL) in CD4-deficient (CD42/2) mice. As in Figure 2, the mice were injected subcutaneously
twice, one week apart, with 100 mg of hsp65-P1 or Mal-P1 in PBS. One week following the second injection, cells from spleen and draining
lymph nodes were pooled and restimulated with 1 mM SYRGL peptide without addition of exogenous cytokines. Six days later the cells were
used as effectors in a standard 4 hr cytolytic assay at various E:T ratios using 51Cr-labeled T2-Kb cells as targets in the presence of 1 mM
SYRGL. Lysis of T2-Kb cells in absence of SYRGL is shown by unfilled symbols.
control Mal-P1. While the cytolytic activity elicited in the suggest a potential mechanism by which the fusion pro-
teins exert their effects in the absence of added adju-CD42/2 mice (n 5 6) was unambiguous, it appeared to
be somewhat less than was generally elicited in normal vants, a prominent feature of the in vivo responses to
all hsp fusion proteins. Generally, where CD4 T cellsC57BL/6 mice. In other experiments, C57BL/6 mice that
had been extensively depleted of CD4 cells by repeated and adjuvants are required for CD8 T cell responses, it
is likely that they function by activating dendritic cellsinjections of an anti-CD4 mAb (GK1.5) also responded
to the standard immunization protocol with hsp65-P1 (Bennett et al., 1998; Ridge et al., 1998; Schoenberger
et al., 1998). The capacity of heat shock fusion proteinsabout as well as untreated normal mice (data not shown).
All of these results show that in stimulating CD8 CTL to directly activate dendritic cells may account for their
ability to bypass the requirements for CD4 T cells andproduction in mice, hsp65-P1 does not require the par-
ticipation of CD4 T cells. The findings do not exclude added adjuvants.
the possibility, however, that CD4 T cells can enhance
the response in normal individuals. Similar evidence that
Hsp Fusion Proteins Activate DendriticCD4 T cells are not essential for the murine CD8 CTL
Cells Directlyresponse to a different hsp fusion protein (M. tuberculo-
Using CTL to detect polypeptide processing by APC,sis hsp70 fused at its N terminus to a fragment of oval-
previous studies pointed to macrophages or equally tobumin) has been obtained in an independent study (Huang
macrophages and dendritic cells as being responsibleet al., 2000).
for processing protein immunogens that elicit CD8 T cell
responses (Kovacsovics-Bankowski and Rock, 1995;
Suto and Srivastava, 1995). We also found that whenDiscussion
macrophages and dendritic cells were incubated with
hsp65-P1, they became equally susceptible to lysis byIn this report we show that mycobacterial hsp65 fused
to the P1 polypeptide activates dendritic cells and stim- peptide-specific CTL in a standard 4 hr cytolytic assay,
indicating that both types of APC could generate smallulates, in the absence of CD41 T cells, the production
of CD81 CTL that recognize a short peptide derived from peptides from the hsp fusion protein and load them on
to MHC class I molecules. However, when these cellsP1. The findings extend the number and diversity of hsp
fusion proteins that can elicit CD8 T cell responses and were evaluated for their ability to stimulate naive CD8
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Table 1. Heat Shock Fusion Proteins Stimulate Increased Expression of MHC and Costimulatory Molecules on Dendritic Cells
Nothing Unmodified hsp65 P1 Peptide hsp65-NP hsp65-P1
MHC Class I 100 105 96 257 151
MHC Class II 63 67 55 279 90
B7.2 60 54 47 129 81
CD40 45 45 47 76 51
Dendritic cells derived from bone marrow of C3H/HeJ mice were incubated for 18 hr with 1.5 3 1026 M of various heat shock fusion proteins
or the control P1 peptide prior to cell surface staining. Numbers are mean fluorescence values.
T cells to proliferate and produce IL-2 and IFNg, the supported by older evidence that hsp65 can serve as
an effective carrier molecule in the classic sense; i.e.,dendritic cells but not the macrophages proved to be
effective. A step toward understanding this difference when chemically coupled to nonimmunogenic hapten-
like molecules (polysaccharides, a malarial peptide), thecomes from the present finding that hsp65-P1 as well
as each of the other hsp65 fusion proteins tested is conjugates elicited IgG antibodies to the adducts in re-
sponses that were presumably T cell dependent (Barrioscapable of directly stimulating dendritic cells to increase
their surface expression of MHC class I and II and costim- et al., 1992). This mechanism is clearly not essential,
because CD42/2 mice injected with hsp65-P1 producedulatory (B7.2) molecules.
Dendritic cells infected with mycobacteria (including cytolytic CD8 T cells to the fusion partner's peptide.
Nevertheless, it is entirely possible that in normal ani-BCG), streptococci, or Leishmania have been shown to
upregulate MHC and costimulatory molecules B7.1 and mals the response may be enhanced by CD4 T cells
specific for peptides derived from the hsp moiety.B7.2 and, in addition, to secrete IL-12 (Henderson et
al., 1997; Rescigno et al., 1998 Demangel et al., 1999; Previous efforts to determine whether CD4 T cells are
essential for CD8 T cell responses to various immuno-Konecny et al., 1999). It may be that microbial cell hsp
molecules are responsible for these effects. If so, our gens and immunization strategies have yielded diverse
results. With some epitopes, e.g., minor histocompatibil-findings (of a difference between hsp65 fusion proteins
and unmodified hsp65) suggest that upregulation of ity antigens, CD8 T cell responses could not be elicited
in CD42/2 mice (Di Rosa and Matzinger, 1996), but withthese activation molecules may be due to the hsp in a
modified form, resembling perhaps the hsp65 fusion more potent immunogens (e.g., lymphocytic choriomen-
ingitis virus or a murine herpes virus) or high doses ofproteins studied here rather than native hsp molecules.
Dendritic cells infected with certain viruses, e.g., influ- particulate antigens, CD8 CTL responses in CD42/2 mice
were virtually the same as those in normal mice (Rahem-enza virus (Ridge et al., 1998), likewise become acti-
vated. However, the hsp fusion proteins appear so far tulla et al., 1991; Rock and Clark, 1996; Stevenson et
al., 1998). That CD4 T cells are not required for the CD8to be the only soluble immunogenic proteins that directly
activate dendritic cells in vitro and in vivo to upregulate T cell response to hsp65-P1 raises the possibility that
hsp fusion proteins are relatively potent immunogensexpression of MHC and costimulatory molecules. Our
experimental system should be useful for investigating for CD8 T cells.
the pathways by which hsp fusion proteins are pro-
cessed and presented by dendritic cells and the mecha- The Hsp Moiety in Hsp Fusion Proteins
nisms by which MHC and costimulatory molecules are In the several hsp fusion proteins examined here, the
upregulated. only common element is hsp65. The question arises as
Diverse hsp bind peptides noncovalently, and studies to how the hsp moiety can directly activate dendritic
of several hsp (gp96, hsp70, calreticulin) have shown cells (and thereby elicit CD8 CTL production) regardless
that they can stimulate CD8 CTL production to bound of wide variations in length and sequence of the fusion
peptides (Srivastava, 1993; Nair et al., 1999). Since these partners. It is particularly notable, in contrast, that un-
hsp±peptide complexes exert their immunogenic effects modified (native) hsp65 lacks this critical activity. It may
without requiring exogenous adjuvants, it will be of inter- be that in the fusion proteins the hsp moiety adopts a
est to determine if, like the hsp65 fusion proteins studied particular conformation or displays a linear sequence,
here, they can also activate dendritic cells directly and peptide motif, or pattern that is (1) necessary for eliciting
elicit CD8 T cell production in the absence of CD4 T cells. the dendritic cell response, (2) retained despite wide
variations in the fusion partner sequences, and (3) ab-
sent or masked in unmodified (native) hsp65. A detailedHsp Fusion Protein Stimulation of CD8 T Cell
Production Does Not Depend structural comparison between the various fusion pro-
teins and native hsp65 will be required to distinguishupon CD4 T Cells
Prior to the present study, one way to account for the between these possibilities.
The intensity of current interest in CD8 vaccines forability of hsp fusion proteins to stimulate CD8 T cell
production was to invoke a key role for CD4 T cells. HIV-1 and other persistent intracellular pathogens as
well as for cancer cells is reflected in recent studies ofThus, a vigorous CD4 T cell response to peptides from
the hsp moiety could activate dendritic cells and amplify diverse genetic vaccines and of several bacterial toxins
fused to antigenic peptides or polypeptides as stimula-an otherwise marginal CD8 T cell response to peptides
from the fusion partner (Bennett et al., 1998; Ridge et tors of CD8 CTL production. For example, nonapeptide
sequences inserted into a truncated subunit of anthraxal., 1998; Schoenberger et al., 1998). This possibility is
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acid analyses and were expressed in molar terms to facilitate com-toxin or pertussis toxin could elicit CD8 CTL in vivo
parisons between proteins and polypeptides of differing molecular(Ballard et al., 1996) and render target cells susceptible
masses. Endotoxin concentrations of recombinant protein prepara-to lysis by cognate CD8 CTL in vitro (Goletz et al., 1997;
tions were determined by the Limulus assay, using reagents and
Carbonetti et al., 1999). These and other bacterial toxins conditions according to Associates of Cape Cod. Peptide concen-
have evidently acquired through evolution the capacity trations were estimated by weight per volume or based on amino
acid analyses.to cross mammalian cell membranes and gain access
to the cell cytosol, where they exert their lethal effects.
Antibodies and Flow CytometryWhile the judicious linkage of small peptides allows
Flow cytometry was carried out on a FACScaliber, using CellQuestthese toxin subunits to retain their ability to traverse
software (Becton Dickinson). Unlabeled or FITC-, PE-, allophycocy-
membranes, the need to preserve this special property anin-, or biotin-labeled antibodies against CD69, CD4, CD8, CD11c,
may limit the size and sequence diversity of the fusion CD11b, GR.1, B7.2, B220, or MHC class I (H-2b) as well as secondary
antibodies and streptavidin labeled with allophycocyanin or PE wereelements that can be accommodated. For the hsp fusion
obtained from PharMingen. 1B2, a clonotypic antibody that recog-proteins, in contrast, there appear so far to be no con-
nizes 2C TCR (Kranz et al., 1984), was purified from the 1B2 hybrid-straints to their effectiveness as CD8 immunogens by
oma and biotinylated using biotinamidocaproate N-hydroxysuccini-the length or sequence of the fusion partners. Because
mide ester (Sigma). The antibody, Y3, is cross-reactive with MHC
large fusion partners, e.g., the equivalent of a typical class I from H-2b (Kb) and H-2k haplotypes. It was affinity purified
protein domain, are likely to encompass many potential from culture supernatants from the Y3 hybridoma (obtained from
American Type Culture Collection) and labeled with fluorescein us-epitopes for diverse MHC class I molecules, the hsp
ing fluorescein isothiocyanate.fusion proteins as a class warrant further study as candi-
date vaccines for use with populations of MHC-dispa-
Generation of Bone Marrow±Derived Dendritic Cellsrate individuals.
and Isolation of Antigen Presenting Cells
and Naive 2C T cells
Experimental Procedures To generate bone marrow±derived dendritic cells from C57BL/6 (or
C3H) mice, bone marrow was flushed from the femur and tibia, red
Mice, CTL Clones, and Cell Lines blood cells were lysed, and the remaining cells were cultured at
C57BL/6 (H-2b), CD4-deficient (CD4 tm1Mak, H-2b), and C3H/HeJ 106 cells/ml in RPMI 1640 medium (supplemented with 10% heat-
mice (H-2k) were obtained from the Jackson Laboratories, main- inactivated fetal calf serum, 2 mM L-glutamine, 10 mM HEPES, 50
tained in barrier cages under specific pathogen-free conditions, and mm b-mercaptoethanol, 100 U/ml penicillin, and 100 mg/ml strepto-
immunized between 4 and 10 weeks of age. 2C TCR transgenic mycin) containing 20 ng/ml murine GM-CSF (R&D Systems). The
mice (H-2b) contain the rearranged transgenes encoding the abTCR medium was replaced on days 2 and 4, and on day 6 the cells
from a 2C CTL clone (Sha et al., 1988). 2C TCR transgenic mice (immature dendritic cells) were harvested for use.
deficient for the recombination activating gene-1 (termed 2C/RAG) In vitro assays were performed with purified cell populations un-
(Manning et al., 1997) were used as a source of naive T cells for in less otherwise noted. Magnetic cell sorting (MACS) was carried
vitro assays (Cho et al., 1999). The 2C CTL clone L3.100 has been out according to the manufacturer's instructions (Miltenyi Biotec).
previously described (Sykulev et al., 1998). EL4 cells were obtained Dendritic cells (splenic or bone marrow derived) were isolated by
from the American Type Culture Collection and T2-Kb cells were a positive sorting using anti-CD11c antibody (purity ranged from 70%±
generous gift from Peter Creswell, Yale University. PBS is (in mM) 97%). Peritoneal lavage macrophages were purified by treating them
140 NaCl, 2.7 KCl, 10 Na, KPO4, PH 7.2. with biotinylated antibodies specific for CD11c, GR.1, and B220,
followed by washing and incubating them with magnetic microbeads
Plasmids, Peptides, and Proteins coated with anti-CD4 or anti-CD8 antibodies or with streptavidin
In the P1 polypeptide, the sequences flanking the N and C termini and then passing them over a negative sorting column. Macrophage
of the SYRGL octapeptide (Figure 1A), from ovalbumin (ova251±257) purity was typically .90%. For purification of 2C T cells from 2C/
and a-ketoglutaraldehyde dehydrogenase, respectively, were modi- RAG transgenic mice, lymph node and spleen cells were coated
fied by addition of a lysine residue penultimate to the N terminus with anti-CD8 magnetic beads (an average of two beads per cell)
(out of ubiquitination considerations) (Eisenlohr et al., 1992; York and positively sorted as above (purity .93%). The purification pro-
and Rock, 1996), and an isoleucine and a tyrosine residue were cedures did not activate APC or T cells as shown by flow cytometry:
added at the N and C termini for cloning purposes. Complementary APC showed no increase in B7.2, MHC class I, or cell diameter, and
oligonucleotides encoding P1 were synthesized and cloned into a T cells showed no CD69 upregulation after 24 hr in culture. There
mammalian expression vector, VR1055 (Vical), and subsequently was also no significant [3H]thymidine incorporation by T cells after
subcloned as an in-frame fusion at the 39 end of the M. bovis BCG 48 hr incubation.
hsp65 gene (hsp65-P1) into the bacterial expression vector pET28A1
(Novagen). The P1 sequence was also subcloned into the 39 end of Cytolytic T Cell Assays
the gene encoding E. coli maltose binding protein in pMAL-p2E, Unless otherwise noted, 51Cr-labeled T2-Kb cells were used as target
using the pMAL protein fusion system (New England Biolabs) as cells. They were incubated with effector cells derived from either
well as into the mammalian expression vector pCIneo (Promega). fusion protein±injected mice or from cultured 2C T cell clones for 4
All hsp65 fusion proteins used in this study as well as the unmodified hr in the presence or absence of SYRGL (1 mM). Specific lysis was
hsp65 were produced as recombinant proteins in E. coli. They were calculated as follows: [(experimental counts 2 spontaneous
purified under denaturing conditions from the soluble fraction of counts)/(total counts 2 spontaneous counts)] 3 100.
bacterial lysates and fractionated successively on butyl-Sepharose, To assess the ability of various APC to process hsp65-P1, den-
Q-Sepharose, Ni-Sepharose when applicable, and finally by dialysis dritic cells and macrophages were used as target cells. Each of
against PBS. Mal-P1 was purified by amylose affinity chromatogra- these cell populations was purified by MACS and then 51Cr labeled
phy (New England Biolabs). for 1 hr at 378C. The labeled cells were then incubated with hsp65-
SDS-PAGE analysis of purified hsp65-P1 revealed a major species P1 together with the 2C CTL clone (L3.100) at a CTL:target cell (E:T)
at 67.5 kDa, which was shown to be hsp65-P1 by Western analysis, ratio of 5:1. Assays were performed in triplicate using 96-well round-
using anti-mycobacterial hsp65±specific antibody (StressGen), and bottom plates, and cell supernatants were counted in a g spectrome-
by electrospray mass spectrometry (MIT Biopolymer Laboratory). ter after 4 hr. Specific lysis was calculated as above.
Mal-P1 was also subjected to amino acid analysis and SDS-PAGE
to confirm molecular weight (45.4 kDa) and purity. P1 and SYRGL Transient Transfection and Antigen Processing Assays
peptides were synthesized by the MIT Biopolymers Laboratory. Pro- EL4 cells (5 3 106) were electroporated with 15 mg of the parent
plasmids or plasmids containing the genes for P1 (in VR1055) ortein concentrations were estimated by bicinchoninic acid or amino
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hsp65-P1 (in pCIneo). Forty-eight hours after transfection, the cells histocompatibility complex class I without involvement of the cyto-
solic class I antigen processing pathway. Infect. Immun. 67,were subjected to centrifugation in Ficoll-Paque (Pharmacia Bio-
tech) (2200 rpm, 20 min), and 106 live cells were incubated with an 602±607.
equal number of splenocytes from naive 2C/RAG mice. After 18 hr Cho, B., Wang, C., Sugawa, S., Eisen, H., and Chen, J. (1999). Func-
the cells were stained with 1B2, anti-CD69, and anti-CD8 antibodies tional differences between memory and naive CD8 T cells. Proc.
(labeled with FITC, PE, and allophycocyanin, respectively), and 2C Natl. Acad. Sci. USA 96, 2976±2981.
T cells were evaluated for upregulation of CD69 by flow cytometry, Demangel, C., Bean, A., Martin, E., Feng, C., Kamath, A., and Britton,
gating on propidium iodide±negative, 1B21CD81 cells. W. (1999). Protection against aerosol Mycobacterium tuberculosis
infection using Mycobacterium bovis Bacillus Calmette Guerin-
Naive 2C T Cell Responses to Dendritic Cells and Macrophages infected dendritic cells. Eur. J. Immunol. 29, 1972±1979.
and Dendritic Cell Activation Assays
Di Rosa, F., and Matzinger, P. (1996). Long-lasting CD8 T cell mem-
Purified dendritic cells and macrophages were incubated with vari-
ory in the absence of CD4 T cells or B cells. J. Exp. Med. 183,
ous concentrations of proteins or peptides in 96-well (5 3 104 cells/
2153±2163.
well) or 48-well (1.5 3 105 cells/well) flat-bottom plates for 24 hr at
Eisenlohr, L., Yewdell, J., and Bennink, J. (1992). Flanking sequences378C. The following day an equal number of purified naive 2C T cells
influence the presentation of an endogenously synthesized peptidewere added to each well (final volume 5 200 ml for the 96-well plates,
to cytotoxic T lymphocytes. J. Exp. Med. 175, 481±487.600 ml for the 48-well plates). After 18 hr, the 48-well plates were
Falk, K., Rotzschke, O., and Rammensee, H. (1992). Specificity ofseparated into (1) cell pellets to analyze 2C T cells for expression
antigen processing for MHC class I restricted presentation is con-of the acute activation marker CD69 by flow cytometry, gating on
served between mouse and man. Eur. J. Immunol. 22, 1323±1326.propidium iodide±negative, 1B21CD81 cells and (2) cell superna-
tants to measure IL-2 secretion (in triplicate, using HT2 cells in a Goletz, T., Klimpel, K., Arora, N., Leppla, S., Keith, J., and Berzofsky,
standard bioassay) (Watson, 1979). After 48 hr, the 96-well plates J. (1997). Targeting HIV proteins to the major histocompatibility
were assayed for IFNg secretion (using 50 ml of cell supernatants complex class I processing pathway with a novel gp120-anthrax
and a capture ELISA assay [R&D Systems]) and for T cell proliferation toxin fusion protein. Proc. Natl. Acad. Sci. USA 94, 12059±12064.
(1 mCi [3H]thymidine [NEN] was added per well, and 16 hr later Gromme, M., Uytdehaag, F., Janssen, H., Calafat, J., van Binnendijk,
the cells were harvested to measure [3H]thymidine incorporation). R., Kenter, M., Tulp, A., Verwoerd, D., and Neefjes, J. (1999). Recy-
Where indicated, 1B2 Fab fragments were added to naive 2C T cells cling MHC class I molecules and endosomal peptide loading. Proc.
at a final concentration of 25 mg/ml. Immature bone marrow±derived Natl. Acad. Sci. USA 96, 10326±10331.
dendritic cells (day 6 of culture) were purified by magnetic sorting
Henderson, R., Watkins, S., and Flynn, J. (1997). Activation of human(.95% CD11b1CD11c1) and incubated (2.5 3 105 cells/well in 96-
dendritic cells following infection with Mycobacterium tuberculosis.well round-bottomed plates) with various fusion proteins or control
J. Immunol. 159, 635±643.proteins. The following day, cells were analyzed by flow cytometry
Huang, Q., Richmond, J.F.L., Suzue, S., Eisen, H.N., and Young,for expression of B7.2 and MHC class I and II molecules, gating on
R.A. (2000). In vivo cytotoxic T lymphocyte elicitation by mycobacte-propidium iodide±negative, CD11c1 cells.
rial heat shock protein 70 fusion proteins maps to a discrete domain
and is CD41 T cell independent. J. Exp. Med. 191, 403±408.Acknowledgments
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